MYR-101
- Generic Name
- MYR-101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the aspartoacylase e...
- Associated Conditions
- -
- Associated Therapies
- -
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Myrtelle Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04833907
- Locations
- 🇺🇸
Dayton Children's Hospital, Dayton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath